NTLA

Intellia Therapeutics, Inc.

12.59 USD

Last updated Oct 9, 04:15 UTC

Yesterday HIGH

$12.41

Yesterday LOW

$11.7

52w HIGH

$28.24

52w LOW

$7.95

EPS

-0.80

PE

-15.74

Next Earnings

Nov 5, 2026

Overview News Unusual Options Flow Insider Transactions Government Trades Fundamentals

Intellia Therapeutics, Inc. stock is up 3.11% since 30 days ago. The next earnings date is Nov 5, 2026. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 27.27% of the previous 10 October’s closed higher than September. In the last 10 Unusual Options Trades, there were 2 PUTs, 8 CALLs. 50% of analysts rate it a buy.

Options Flow Last 10
Date & Time	Expiration Date	Strike Price	Trade Type	Size	Open Interest

22 Sep 17:54	21 Jan, 2028	10.00	PUT	150	885
22 Sep 18:09	16 Oct, 2026	13.00	CALL	393	1243
24 Sep 13:45	16 Oct, 2026	10.00	CALL	150	541
24 Sep 13:45	16 Oct, 2026	10.00	CALL	200	541
24 Sep 15:31	16 Oct, 2026	10.00	CALL	150	541
25 Sep 14:04	16 Oct, 2026	10.00	CALL	311	880
25 Sep 14:08	16 Oct, 2026	10.00	CALL	300	880
25 Sep 19:21	16 Oct, 2026	30.00	PUT	15	0
29 Sep 19:56	21 Jan, 2028	10.00	CALL	50	2062
05 Oct 14:12	15 Jan, 2027	35.00	CALL	2000	3795

Advanced Data Unlock

Avi Kapoor

Wed Jun 17, 2026

Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with the Dow Jones gaining 200 points on Wed. Jabil Inc (JBL) shares surged 9.8% after beating earnings & revenue estimates. Other big gainers included QURE, CLPT, JLHL, BRAI, LZB, HQ, SHAZ, WNC, RXT, ARQQ, and MFI.
Benzinga Newsdesk

Mon Jun 15, 2026

Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price Target

Citizens analyst Silvan Turkcan reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Market Outperform and maintains $30 price target.
Benzinga Newsdesk

Mon Jun 15, 2026

Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price Target

Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $12 price target.
Vandana Singh

Mon Jun 15, 2026

Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder

Intellia shares rise after new Phase 3 lonvo-z data showed significant reductions in HAE attacks and reinforced its regulatory outlook.
Benzinga Newsdesk

Mon Jun 15, 2026

HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price Target

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Buy and maintains $25 price target.
Benzinga Newsdesk

Mon Jun 15, 2026

Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of Medicine

Data from HAELO Phase 3 clinical trial presented today in a late-breaking oral session at European Academy of Allergy & Clinical Immunology Annual Congress 2026HAELO manuscript simultaneously published in the New
Benzinga Newsdesk

Mon Jun 1, 2026

Intellia Therapeutics To Highlight Data From Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema In Late-Breaking Oral Presentation At EAACI Annual Congress 2026

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global
Benzinga Newsdesk

Mon Jun 1, 2026

Intellia Therapeutics Announces That Data From The Global Phase 3 HAELO Clinical Trial Of Lonvo-Z In Hereditary Angioedema Will Be Presented At The European Academy Of Allergy & Clinical Immunology Annual Congress 2026

Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.Late-Breaking Oral Presentation Details:Title: HAELO, a Phase 3, Global, Randomised,
Benzinga Newsdesk

Wed May 13, 2026

Bernstein Maintains Market Perform on Intellia Therapeutics, Raises Price Target to $17

Bernstein analyst William Pickering maintains Intellia Therapeutics (NASDAQ:NTLA) with a Market Perform and raises the price target from $13 to $17.
Avi Kapoor

Wed May 13, 2026

Aramark To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Wednesday

Top Wall Street analysts updated their ratings on top companies. For full list of changes, including upgrades/downgrades, see our analyst ratings page.

Barclays

Tue Oct 6, 14:08

sell

initial
Citizens

Wed Sep 9, 15:01

buy

confirm
Wedbush

Wed Sep 9, 14:17

hold

confirm
HC Wainwright & Co.

Wed Sep 9, 12:32

buy

confirm